IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 226-250 out of 1269.

<< < 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 > >>

Public Release: 3-Feb-2015
Genome Biology
Culture shock -- Are lab-grown cells a faithful model for human disease?
Cell cultures used in research may not act as a faithful mimic of real tissue, according to research published in Genome Biology. Laboratory-grown cells experience altered cell states within three days as they adapt to their new environment. Studies of disease, including cancer, rely on cell cultures that have often been grown for decades. The findings could affect the interpretation of past studies and provide important clues for improving cell cultures in the future.

Contact: Joel Winston
Joel.Winston@biomedcentral.com
44-020-319-22081
BioMed Central

Public Release: 3-Feb-2015
British Journal of Cancer
One in 2 people in the UK will get cancer
One in two people will develop cancer at some point in their lives, according to the most accurate forecast to date from Cancer Research UK, and published in the British Journal of Cancer.
Cancer Research UK

Contact: Greg Jones
greg.jones@cancer.org.uk
44-203-469-8311
Cancer Research UK

Public Release: 3-Feb-2015
ecancermedicalscience
Sparing hope for the future: Preserving fertility in cancer patients
While families around the world delay childbearing to later in life, cancer diagnoses are affecting people ever earlier in life. When these lifestyle trends collide, we see an increasing number of young women rendered infertile by cancer or cancer treatments. What can be done about it? What do doctors need to know? And does a cancer diagnosis mean that a patient can never have children?

Contact: Katie Foxall
katie@ecancer.org
44-779-101-9469
ecancermedicalscience

Public Release: 3-Feb-2015
Oncotarget
MicroRNAs can limit cancer spread
In cancer patients with limited spread, certain microRNAs suppress tumor cells' ability to adhere to other cell types, invade tissues and migrate to distant sites, the hallmarks of metastasis. This could predict how aggressively a tumor can spread and guide treatment.
Virginia and D.K. Ludwig Fund for Cancer Research, Lung Cancer Foundation, Prostate Cancer Foundation, Foglia Family

Contact: John Easton
John.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 2-Feb-2015
Nature Communications
Epigenetic signatures that differentiate triple-negative breast cancers
Australian researchers have identified epigenetic 'signatures' that could help clinicians tell the difference between highly aggressive and more benign forms of triple-negative breast cancer.
National Breast Cancer Foundation

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research

Public Release: 2-Feb-2015
Journal of Clinical Investigation
Activated immune cells indicate a favorable prognosis in colorectal cancer
When cytotoxic T cells are activated, they produce TNF alpha that helps mediate immune responses. Scientists from Heidelberg and Dresden have now linked rising levels of TNF alpha in tumor tissue to increasing numbers of activated killer cells that specifically recognize the tumor and are capable of fighting it. High levels of TNF alpha in a tumor prove to be an independent prognostic indicator for a favorable course of the disease.

Contact: Sibylle Kohlstädt
s.kohlstaedt@dkfz.de
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Public Release: 2-Feb-2015
Journal of Clinical Oncology
Which breast cancer patients need lymph nodes removed? Ultrasound narrows it down, study finds
Which breast cancer patients need to have underarm lymph nodes removed? Mayo Clinic-led research is narrowing it down. A new study finds that not all women with lymph node-positive breast cancer treated with chemotherapy before surgery need to have all of their underarm nodes taken out. Ultrasound is a useful tool for judging before breast cancer surgery whether chemotherapy eliminated cancer from the underarm lymph nodes, the researchers found. The findings are published in the Journal of Clinical Oncology.

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 2-Feb-2015
Nature Methods
Scientists open new chapter in cell biology and medicine
An entirely new approach for the mechanical characterization of cells, developed by scientists of the Technische Universität Dresden, has the potential to revolutionize the diagnosis of a wide range of diseases.

Contact: Dr. Jochen Guck
jochen.guck@tu-dresden.de
49-035-146-340-330
Technische Universität Dresden

Public Release: 2-Feb-2015
Cancer Prevention Research
Metformin may lower lung cancer risk in diabetic nonsmokers
Among nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk.
National Institutes of Health

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 2-Feb-2015
Nature
New pathway for stalling BRCA tumor growth revealed
Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations which, in turn, are closely tied to breast and ovarian cancers, according to researchers at NYU Langone Medical Center.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 2-Feb-2015
FASEB Journal
New method shrinks metastatic ovarian cancer and reduces chemotherapy dose
New research published in the February 2015 issue of The FASEB Journal may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery.

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology

Public Release: 2-Feb-2015
British Journal of Surgery
Surgical innovations brought to you by the British Journal of Surgery
Special issue of the British Journal of Surgery highlights surgical innovations.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 2-Feb-2015
Cell Cycle
Dartmouth researchers discover new mechanism of acquired resistance to breast cancer drugs
In the search for new approaches to treat ERBB2 -- also known as HER2 -- positive breast cancers that have become drug-resistant, Dartmouth investigator Manabu Kurokawa, Ph.D., led a team in discovery of a novel cancer resistance mechanism.
National Institutes of Health

Contact: Kirk Cassels
kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 2-Feb-2015
PLOS ONE
Moffitt researchers discover biological markers associated with high-risk pancreatic lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will live five years after their diagnosis. One reason for this high mortality rate is the lack of effective tools to detect pancreatic cancer early enough to allow its surgical removal. Moffitt Cancer Center researchers are now one step closer to devising an approach to detect pancreatic cancer earlier.
American Chemical Society, NIH/National Cancer Institute

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 2-Feb-2015
Journal of Thoracic Disease
Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
'Increasingly physicians are being presented with health economic analyses in mainstream medical journals as a means of potentially influencing their prescribing. However, it is only when you understand the multiple assumptions behind these calculations that you can see that they are by no means absolute truths,' says D. Ross Camidge, M.D., Ph.D., investigator at the University of Colorado Cancer Center.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 30-Jan-2015
Nature Communications
Scientists home in on reasons behind cancer drug trial disappointment
Scientists have discovered a 'hidden' mechanism which could explain why some cancer therapies which aim to block tumor blood vessel growth are failing cancer trials. The same mechanism could play the role in the bacterial or viral septic shock -- e.g. in Ebola fever -- by destabilizing the blood vessels.

Contact: Dr. Pipsa Saharinen
pipsa.saharinen@helsinki.fi
358-504-486-361
University of Helsinki

Public Release: 30-Jan-2015
Nature Communications
Hot on the trail of the hepatitis-liver cancer connection
Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer.

Contact: Jens Wilkinson
jens.wilkinson@riken.jp
81-484-621-225
RIKEN

Public Release: 30-Jan-2015
PLOS ONE
Moffitt study find loss of certain protein is associated with poor prognosis in breast, lung cancer
Moffitt Cancer Center researchers have found that breast and lung cancer patients who have low levels of a protein called tristetraprolin have more aggressive tumors and a poorer prognosis than those with high levels of the protein. Their study was published in the Dec. 26 issue of PLOS ONE.
NIH/National Cancer Institute

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 30-Jan-2015
EBioMedicine
UTSW study links deficiency of cellular housekeeping gene with aggressive forms of breast cancer
UT Southwestern Medical Center scientists have identified a strong link between the most aggressive type of breast cancer and a gene that regulates the body's natural cellular recycling process, called autophagy.
National Institutes of Health, Cancer Prevention and Research Institute of Texas

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 30-Jan-2015
Neurosurgery
Fluorescent dyes 'light up' brain cancer cells, reports Neurosurgery
Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 30-Jan-2015
Nature Communications
Master switch found to stop tumor cell growth by inducing dormancy
Commonly used anticancer drugs may help to make tumor cells dormant.
The Samuel Waxman Cancer Research Foundation, NIH/National Cancer Institute, NIH/National Institute of Environmental Health Sciences, New York State Stem Cell Science program, JJR Foundation and Hirschl/Weill-Caulier Trust, Department of Defense, Janssen

Contact: Lucia Lee
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 30-Jan-2015
Science of the Total Environment
Arsenic stubbornly taints many US wells, say new reports
Naturally occurring arsenic in private wells threatens people in many US states and parts of Canada, according to a package of a dozen scientific papers to be published next week. The studies, focused mainly on New England but applicable elsewhere, say private wells present continuing risks due to almost nonexistent regulation in most states, homeowner inaction and inadequate mitigation measures.
NIH/National Institute of Environmental Health Sciences Superfund Research Program

Contact: Kevin Krajick
kkrajick@ei.columbia.edu
212-854-9729
The Earth Institute at Columbia University

Public Release: 29-Jan-2015
Nucleic Acids Research
CNIO researchers broaden the catalogue of biological chimeras for the study of the genome
The team led by Alfonso Valencia gathers 29,000 biological chimeras from eight species, including humans, mice and yeast. The catalog is a very valuable source of information for cancer research, and it could reveal new markers and potential targets for the development of new cancer drugs.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 29-Jan-2015
Journal of Thoracic Oncology
Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Multiplexed genetic screening for epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer setting in the United States.

Contact: Murry Wynes
Murry.Wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 29-Jan-2015
Cell Cycle
Fox Chase researchers reveal how pancreatic cancer cells sidestep chemotherapy
Research led by Timothy J. Yen, Ph.D., professor at Fox Chase Cancer Center, reveals that one reason pancreatic cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy. They hijack the vitamin D receptor, normally associated with bone health, and re-purposed it to repair the damage caused by chemotherapy.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center

Showing releases 226-250 out of 1269.

<< < 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 > >>

  Search News Releases

     

 

EurekAlert!